Pharmaceutical Plastic Packaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Pharmaceutical Plastic Packaging Market is projected to expand from USD 79.61 Billion in 2025 to USD 116.62 Billion by 2031, registering a CAGR of 6.57%. This sector encompasses a wide variety of polymeric containment products, such as rigid bottles, vials, blister packs, and prefilled syringes, all engineered to maintain drug stability and guarantee patient safety. The market is primarily driven by the rising global incidence of chronic illnesses and an aging demographic that requires dependable medication delivery systems. Additionally, the inherent benefits of plastics, including their durability, lightweight composition, and superior design adaptability compared to conventional glass, continue to foster their adoption in pharmaceutical logistics.

Despite this growth, the industry faces a major obstacle due to mounting environmental oversight and strict regulatory frameworks regarding plastic waste. Manufacturers are compelled to manage these sustainability demands while strictly adhering to rigorous safety standards. The scale of the sector is significant; according to the Flexible Packaging Association, medical and pharmaceutical applications represented roughly 17% of flexible packaging demand in 2024. This considerable market share highlights the magnitude of the challenge as the industry attempts to balance essential healthcare requirements with evolving environmental mandates.

Market Drivers

The growth of the biologics and injectable drug markets is fundamentally transforming the landscape of pharmaceutical plastic packaging, necessitating high-performance containment capabilities. As complex large-molecule therapies and GLP-1 weight-loss drugs gain popularity, manufacturers are increasingly shifting toward advanced polymer syringes and auto-injectors that offer superior break resistance and dimensional precision compared to traditional glass. This structural change is translating directly into revenue increases for specialized producers. For instance, Gerresheimer reported in September 2024 that its Plastics & Devices division achieved 9.2% organic revenue growth for the first nine months of the year, a performance largely attributed to the robust demand for these medical plastic systems.

Concurrently, the adoption of sustainable and eco-friendly packaging solutions has become a critical priority, forcing the industry to balance safety with circular economy principles. Companies are aggressively integrating post-consumer recycled (PCR) resins and lightweight designs to comply with tightening environmental regulations and client sustainability goals. According to Amcor’s '2024 Sustainability Report' released in October 2024, the company procured over 224,000 metric tons of recycled material globally to support the transition toward circular packaging portfolios. This drive for scale and sustainability is also triggering major industrial consolidation, evidenced by Amcor’s 2024 announcement of a definitive agreement to acquire Berry Global for approximately $8.4 billion, a move set to reshape the global healthcare packaging supply chain.

Market Challenges

Strict regulatory frameworks and intensifying environmental scrutiny regarding plastic waste represent a formidable barrier to the growth of the Global Pharmaceutical Plastic Packaging Market. This regulatory pressure hampers market progress by compelling manufacturers to allocate significant resources toward compliance efforts rather than capacity expansion or innovation in standard logistics. Companies must navigate a complex landscape of new laws demanding recyclability and waste reduction, often necessitating expensive reformulation of packaging materials to ensure they meet both sustainability mandates and critical drug safety standards. The need to validate these eco-friendly alternatives creates operational bottlenecks, effectively slowing the time-to-market for pharmaceutical products and increasing overall production costs.

The immense volume of material used in the sector amplifies the urgency of these regulations, thereby increasing the burden of compliance. According to the Healthcare Plastics Recycling Council, in 2024, global healthcare plastics production was projected to reach 48 billion pounds by 2025. This significant figure illustrates the massive environmental footprint that regulators intend to curtail, consequently tightening the constraints under which the pharmaceutical packaging industry must operate.

Market Trends

The implementation of on-pack anti-counterfeiting serialization is fundamentally reshaping the sector as manufacturers align with rigorous track-and-trace mandates like the Drug Supply Chain Security Act. This trend necessitates the integration of 2D data matrix barcodes and tamper-evident features directly onto plastic bottles and vials to ensure end-to-end supply chain visibility and patient safety. The industry has made substantial progress in establishing the digital infrastructure required for this transparency, moving beyond basic regulatory compliance to operational optimization. As noted by the Healthcare Distribution Alliance in August 2025, a member survey indicated that the median level of accurate data exchange between trading partners at the piece level had reached 98.5% as of early June, signaling a mature adoption of these security protocols.

Simultaneously, the integration of smart adherence tracking technologies is transforming standard plastic packaging into connected digital assets. By embedding Radio Frequency Identification inlays and Near Field Communication tags into labels and closures, pharmaceutical companies are enabling automated inventory management and real-time medication verification in hospital settings. This connectivity addresses critical challenges in stock visibility and drug integrity while streamlining clinical workflows. According to a press release from Schreiner MediPharm in August 2025, the company's collaboration with KitCheck has successfully captured over 325 million units of injectable emergency and anesthetic drugs to date, highlighting the substantial industrial scale of adoption for these intelligent packaging systems.

Key Players Profiled in the Pharmaceutical Plastic Packaging Market

• Gerresheimer AG
• Amcor PLC
• Berry Plastics Group Inc.
• Aptar Group Inc.
• Berk Company LLC
• Pretium Packaging LLC
• Klockner Pentaplast Group Ltd.
• Comar LLC
• Gil Plastic Products Ltd.
• Drug Plastics Group Inc.

Report Scope

In this report, the Global Pharmaceutical Plastic Packaging Market has been segmented into the following categories:

Pharmaceutical Plastic Packaging Market, by Raw Material:

• Polypropylene (PP)
• Polyethylene Terephthalate (PET)
• Low Density Polyethylene (LDPE)
• High Density Polyethylene (HDPE)
• Other

Pharmaceutical Plastic Packaging Market, by Product Type:

• Solid Containers
• Dropper Bottles
• Nasal Spray Bottles
• Liquid Bottles
• Oral Care
• Pouches
• Vials and Ampoules
• Cartridges
• Syringes
• Caps and Closures
• Other

Pharmaceutical Plastic Packaging Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Plastic Packaging Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.